 HAYWARD, Calif., Sept. 8, 2021 PRNewswire -- Benitec Biopharma Inc. NASDAQ: BNTC, a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an update on the ongoing analyses of the large animal subjects treated with BB-301 in the Pilot Dosing Study. 